This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Abbott (ABT) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Abbott (ABT) closed at $102.82, marking a +0.8% move from the previous day.
Abbott (ABT) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed at $102 in the latest trading session, marking a +0.29% move from the prior day.
Abbott (ABT) Reports Upbeat Cardiomems Sensor Study Result
by Zacks Equity Research
Abbott's (ABT) MONITOR-HF is the third randomized, controlled trial that will provide significant health benefits to indicated heart failure patients.
Should You Invest in the iShares U.S. Medical Devices ETF (IHI)?
by Zacks Equity Research
Sector ETF report for IHI
Abbott (ABT) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Abbott (ABT) closed at $102.14, marking a -1.83% move from the previous day.
Abbott (ABT) Unveils Late-Breaking Data on Leadless Pacemaker
by Zacks Equity Research
Abbott (ABT) study analyzes primary safety and efficacy endpoints in the first 300 people enrolled across 55 centers in the United States, Canada and Europe.
Abbott (ABT) Expands in Electrophysiology With New FDA Nod
by Zacks Equity Research
Abbott (ABT) notes that using TactiFlex catheter can lead to reduced procedure times and better safety compared to the company's previous generation catheters.
Abbott's (ABT) Assert-IQ Cardiac Monitor Receives FDA Approval
by Zacks Equity Research
Abbott's (ABT) latest approval adds to its line-up of remote patient management and treatment tools that can support doctors more effectively.
Abbott (ABT) Down 1.7% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Abbott (ABT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Abbott's (ABT) New Pact to Advance Clinical Trials Diversity
by Zacks Equity Research
Abbott's (ABT) latest additions to Diversity in Clinical Trials effort expand upon the alliances, awards and the emphasis on diverse participation in its own clinical trials.
Here's Why You Should Retain Abbott (ABT) Stock For Now
by Zacks Equity Research
Investors are optimistic about Abbott (ABT) on continued growth in the core Diagnostics arm.
Abbott (ABT) EPD Business Grows Strong, Macro Issues Stay
by Zacks Equity Research
Abbott (ABT) continues to make good progress, increasing manufacturing production and recovering market share in the Nutrition business.
Cigna (CI) Q1 Earnings Surpass Estimates, Ups '23 EPS View
by Zacks Equity Research
Cigna's (CI) first-quarter 2023 results indicate a strong contribution to revenues from Evernorth Health Services and Cigna Healthcare businesses. Management currently expects adjusted EPS to be a minimum of $24.70 in 2023.
The Zacks Analyst Blog Highlights Berkshire Hathaway, Tesla, JPMorgan Chase, Abbott Laboratories and Comcast
by Zacks Equity Research
Berkshire Hathaway, Tesla, JPMorgan Chase, Abbott Laboratories and Comcast are included in this Analyst Blog.
Top Research Reports for Berkshire Hathaway, Tesla & JPMorgan Chase
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Berkshire Hathaway Inc. (BRK.B), Tesla, Inc. (TSLA) and JPMorgan Chase & Co. (JPM).
Acadia Healthcare (ACHC) Q1 Earnings Beat on Higher Patient Volumes
by Zacks Equity Research
Acadia Healthcare's (ACHC) Q1 results reflect higher revenue per patient day, partly offset by an elevated cost level. Management reaffirms its 2023 business guidance.
The Zacks Analyst Blog Highlights BioRad Laboratories, Henry Schein, Insulet, Abbott and LabCorp
by Zacks Equity Research
BioRad Laboratories, Henry Schein, Insulet, Abbott and LabCorp are included in this Analyst Blog.
3 MedTech Stocks Likely to Beat Estimates in Q1 Earnings
by Urmimala Biswas
MedTech companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how BIO, HSIC and PODD are poised ahead of their earnings releases.
Centene (CNC) Q1 Earnings Miss Estimates, '23 EPS View Raised
by Zacks Equity Research
Centene's (CNC) first-quarter 2023 results grapple with higher operating expenses, partly offset by an expanding customer base. Management presently expects adjusted EPS to be at least $6.40 in 2023.
NUVA vs. ABT: Which Stock Is the Better Value Option?
by Zacks Equity Research
NUVA vs. ABT: Which Stock Is the Better Value Option?
HCA Healthcare (HCA) Beats on Q1 Earnings, Ups '23 EPS View
by Zacks Equity Research
HCA Healthcare's (HCA) first-quarter results gain from increased patient admissions. Management expects EPS within the $17.25-$18.55 band this year, higher than the previous view of $16.40-$17.60.
Abbott's (ABT) Q1 Earnings Beat Estimates, Margins Down
by Zacks Equity Research
Double-digit organic growth in Diabetes Care, Structural Heart, Heart Failure and Neuromodulation contributed to Abbott's (ABT) Q1 revenues.
Abbott (ABT) Reports Q1 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for Abbott (ABT) give a sense of how its business performed in the quarter ended March 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Abbott (ABT) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Abbott (ABT) delivered earnings and revenue surprises of 5.10% and 1.07%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Abbott (ABT) Gets FDA Clearance for FreeStyle Libre 3 Reader
by Zacks Equity Research
Abbott (ABT) receives the FDA clearance for a standalone reader to be used for the FreeStyle Libre 3 iCGM system.